Vaccine developer Vaxcyte has floated in an upsized initial public offering having raised $110m in a Roche-backed round just three months ago.

Pharmaceutical firm Roche has scored an exit after US-based vaccine developer Vaxcyte floated on the Nasdaq Global Select Market in a $250m initial public offering.

The company priced more than 15.6 million shares at $16.00 each having previously set a range of $14 to $16 for 14 million shares. It floated on Friday and its shares had risen to $28.52 at close of trading yesterday.

Formerly known as SutroVax, Vaxcyte was spun off by biopharmaceutical company Sutro Biopharma and…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn